Cytokinetics Inc [CYTK] stock is trading at $49.94, down -1.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CYTK shares have gain 9.18% over the last week, with a monthly amount glided 2.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on January 22, 2025, when Stifel initiated its Buy rating and assigned the stock a price target of $80. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on November 08, 2024, and set its price target to $80. On August 13, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $60 on the stock. UBS downgraded its rating to a Neutral and increased its price target to $92 on January 24, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and raised its price target to $90 on January 05, 2024. Goldman started tracking with a Buy rating for this stock on November 09, 2023, and assigned it a price target of $50. In a note dated November 07, 2023, B. Riley Securities initiated an Buy rating and provided a target price of $66 on this stock.
Cytokinetics Inc [CYTK] stock has fluctuated between $44.49 and $84.05 over the past year. Currently, Wall Street analysts expect the stock to reach $90 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $49.94 at the most recent close of the market. An investor can expect a potential return of 80.22% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Cytokinetics Inc [NASDAQ:CYTK] reported sales of 3.22M for the trailing twelve months, which represents a growth of 22.49%. Gross Profit Margin for this corporation currently stands at -28.72% with Operating Profit Margin at -162.98%, Pretax Profit Margin comes in at -179.06%, and Net Profit Margin reading is -179.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 3.35 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -56.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 48.50 points at the first support level, and at 47.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.09, and for the 2nd resistance point, it is at 54.24.
Ratios To Look Out For
For context, Cytokinetics Inc’s Current Ratio is 9.28. Further, the Quick Ratio stands at 9.28, while the Cash Ratio is 0.43. Considering the valuation of this stock, the price to sales ratio is 1830.32.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Jan 21 ’25 when 2000.0 shares were sold. EVP Research & Development, Malik Fady Ibraham completed a deal on Jan 07 ’25 to sell 2000.0 shares. Meanwhile, Officer FADY MALIK bought 12000.0 shares on Jan 07 ’25.
